EMEA-001636-PIP01-14-M03 - paediatric investigation plan

Vericiguat

Key facts

• Invented name:
  Verquvo
• Active Substance:
  Vericiguat
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/0454/2022
• PIP number:
  EMEA-001636-PIP01-14-M03
• Pharmaceutical form(s):
  • Tablet
  • Age-appropriate oral liquid dosage form
• Condition(s) / indication(s):
  Treatment of left ventricular failure
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  28/10/2022

Decision

P/0454/2022 : EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for vericiguat (Verquvo), (EMEA-001636-PIP01-14-M03)

AdoptedReference Number: EMA/775666/2022